Medicine Archives - Page 2 of 5

Taylor Boyd – PharmaTimes

Abzena has appointed Taylor Boyd as Chief Business Officer Abzena has announced the appointment of Taylor Boyd to the newly

UKHSA announces new effort to tackle hepatitis C

The agency has launched a whole genome sequencing service to monitor the virus The UK Health Security Agency (UKHSA) has

Head start – PharmaTimes

How to choose the best telemedicine provider for neurology As hospitals navigate the evolving landscape of healthcare, telemedicine has emerged

Track record – PharmaTimes

Top 5 platforms for measurement-based care in 2025 Measurement-based care (MBC) enhances clinical and therapeutic outcomes through client-reported data and

Anocca announces authorisation pancreatic cancer trial

VIDAR-1 trial marks company’s clinical-stage debut Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone

Pfizer’s Talzenna therapy accepted for use within NHS Scotland

Scottish Medicines Consortium approves new option for mCRPC patients Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has

Grifols clinical trial shows positive results for post-polio patients

Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating

Rxulti approved in the European Union for adolescent schizophrenia

EC extends brexpiprazole indication to include adolescents Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved

Orphelia Pharma explores other pathways for paediatric cancer treatment

Company seeks new direction after negative CHMP opinion on KIZFIZO Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after

Minoryx doses first patient with leriglitazone in Rett syndrome study

Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in its phase

New weight-loss pill shows promising results

Oxford Medical Products targets overweight individuals Oxford Medical Products has announced positive three-month clinical trial results for Sirona, a weight-loss

Dementia drug neflamapimod shows positive phase 2b trial results

CervoMed’s therapy demonstrates significant improvement in patients CervoMed has announced positive results from the extension phase 2b RewinD-LB study of

Agomab announces positive phase 2a interim results for AGMB-129

FSCD therapy meets all endpoints in interim analysis Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients

NHS patients receive UK-donated plasma medicines for first time in 30 years

Octapharma supports NHS in building resilient supply chain Octapharma has announced that, for the first time in almost 30 years,

Leqembi enters second consultation period following NICE draft guidance update

NICE convenes third committee meeting for additional appraisal consideration Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will

Rotherham NHS Foundation Trust enhances patient engagement

Innovative digital transformation leads to significant improvements To reduce waiting lists and enhance patient communication, Rotherham NHS Foundation Trust has

SECuRE trial pre-chemo participants experience PSA level drops

Cohort expansion phase commences with promising results The Safety Review Committee (SRC) has confirmed the end of the Dose Escalation

Centauri therapeutics selects first ABX-01 clinical candidate

Lead candidate for lung infections moves to human trials Centauri Therapeutics Limited has announced the selection of its first clinical

Bas Vorsteveld – PharmaTimes

Kenvue appoints Bas Vorsteveld as Managing Director for Northern Europe Kenvue has appointed Bas Vorsteveld as Area Managing Director for Northern Europe. He will oversee

Blood cancer patients face treatment access disparity

New research highlights NHS approval gap compared to other cancers Research from the Blood Cancer Alliance reveals a significant disparity

Professor Dr Uli Brödl – PharmaTimes

Grünenthal has appointed Professor Dr Uli Brödl as CSO Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO)

Chain reaction – PharmaTimes

Pharmaceutical manufacturers in the UK have been navigating complex supply chains for the longest time, balancing the dual pressures of

Pharma unphased

The critical step of navigating post-approval phase

Brainomix partners with Medtronic to enhance stroke care

New collaboration aims to integrate AI solutions for treatment Brainomix, a leader in stroke AI imaging software, has announced a

Datapharm collaborates with VIDAL to improve medicines information access in France

New partnership to integrate SRD search technology Datapharm, a UK-based provider of medicines information, has announced its expansion into Europe

Mitazalimab shows promising survival rates in cancer study

Updated data from phase 2 study reveals survival benefit Alligator Bioscience has announced updated results from its phase 2 OPTIMIZE-1

Microbiotica unveils new data on MB097 at AACR IO meeting

Data presented in Los Angeles showcases therapy’s potential Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at

Dubai garden blooms with Boehringer Ingelheim’s lung disease campaign

Awareness of interstitial lung disease raised at Miracle Garden Boehringer Ingelheim, a leading biopharmaceutical company, has teamed up with the

Rishi Sunak joins Prostate Cancer Research as an ambassador

Former UK PM advocates for national screening programme Rishi Sunak has joined Prostate Cancer Research as an ambassador to champion

Mukhtar Ahmed – PharmaTimes

BC Platforms has appointed Mukhtar Ahmed as CEO BC Platforms has announced that it has appointed Mukhtar Ahmed as its

ICR researchers develop blood test to uncover how childhood tumours adapt

It is hoped that the approach will lead to more targeted treatments for childhood cancers Researchers from the Institute of

Stephan Fritschi – PharmaTimes

Carbogen Amcis has appointed Stephan Fritschi as CEO Carbogen Amcis has appointed Stephan Fritschi, who is currently serving as the

FDA approves Deciphera’s Romvimza for rare tumour type

Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations The US Food and Drug Administration (FDA) has

Brent Shafer – PharmaTimes

Baxter has appointed Brent Shafer as Chair and Interim CEO Baxter International has appointed Brent Shafer, who has been serving

UK study highlights importance of GP data in understanding atrial fibrillation

The common heart condition affects approximately 1.5 million people in the UK A new UK study has highlighted the critical

Heather Knight – PharmaTimes

Baxter has appointed Heather Knight as Executive Vice President and COO Baxter International has appointed Heather Knight, who has been

NHS England launches first-ever breast cancer screening campaign

New data has shown that around a third of women do not attend screenings after being invited NHS England has

Bath researchers awarded Wellcome grant for psychotic disorder study

New funding to investigate cognitive decline and brain ageing The University of Bath has received a £3.5 million Wellcome grant

Cambridge scientists develop ‘super test’ for prostate cancer

New test aims to revolutionise prostate cancer screening Scientists in Cambridge have developed a new ‘super test’ for prostate cancer

Illuccix therapy gets approval in the UK

Imaging agent to improve prostate cancer detection Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency

Andembry treatment approved across Europe

Significant progress for hereditary angioedema condition Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY

Bimekizumab shows long-term efficacy in hidradenitis suppurativa

UCB’s BIMZELX reveals promising two-year data at EHSF 2025 UCB has announced impressive two-year data for BIMZELX (bimekizumab) at the

Amlenetug receives FDA Fast Track Designation

Potential treatment for multiple system atrophy shows promise Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the

Lynparza approved in Scotland for BRCA-mutated breast cancer patients

Treatment expands options for HER2-negative metastatic breast cancer AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use

Libtayo available in Scotland for cervical cancer patients

New immunotherapy offers hope for recurrent cervical cancer Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has

Hemgenix shows efficacy among haemophilia B patients

CSL Behring’s study reveals significant long-term benefits New data from CSL Behring’s HOPE-B study demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) gene

Capgemini unveils AI breakthrough to boost bioeconomy

New methodology may boost innovation in protein engineering Capgemini has introduced a pioneering generative AI-driven methodology for protein engineering, utilising

FDA grants Orphan Drug Designation to Ariceum cancer therapy

Designation follows promising preclinical data and FDA clearance Ariceum Therapeutics, a private biotech company based in Berlin, has announced that

Qureight and Avalyn launch strategic partnership in pulmonary fibrosis

Partnership aims to leverage cutting-edge technology in clinical trials Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership

Novartis secures MHRA authorisation for ribociclib

Breast cancer therapy offers hope for patients at risk of recurrence Novartis UK announced the Medicines and Healthcare products Regulatory

Rippon Ubhi – PharmaTimes

Sanofi’s Rippon Ubhi appointed new Chair of European Medicines Group Sanofi has announced that Rippon Ubhi has been appointed as the new Chair

Algiax announces results from phase 2a trial for neuropathic pain treatment

Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments

Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies

Partnership aims to create recombinant nanobodies to treat immune disorders Grifols, a global healthcare company and leading manufacturer of plasma-derived

CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients

Positive opinion issued for marketing authorisation extension The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing

Aplagon secures EUR 7 million for APAC phase 2a trials

Funding led by new investors FSG and EIC Fund Helsinki-based Aplagon has raised EUR 7 million to advance its APAC

Research resolutions – PharmaTimes

Diversity remains high on the agenda for those designing and delivering clinical trials with the aim of bringing new treatments

Network of trust – PharmaTimes

How the emc supports the accessibility of medicines information Distributing reliable information about medicines is challenging for the pharma industry

Janine Schuurman – PharmaTimes

Commit Biologics has appointed Janine Schuurman to its board Commit Biologics has announced the appointment of Janine Schuurman to its Board of Directors. Janine is

Paula Sutherland – PharmaTimes

Alliance Healthcare has appointed Paula Sutherland as Sales Director Alliance Healthcare UK has announced that Paula Sutherland has been appointed to the position of Sales

FDA approves new Alzheimer’s treatment regimen

Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA)

Cartesian Therapeutics announces FDA agreement for new trial

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the

Alligator Bioscience reports survival benefit of mitazalimab with mFOLFIRINOX

Comparison shows improved survival rates for pancreatic cancer treatment Alligator Bioscience has announced positive outcomes from indirect treatment comparison studies,

Vedanta Biosciences reveals Phase 2 VE303 results

Study highlights VE303’s potential in reducing recurrent CDI Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study

Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol

Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results from its

Zydus announces USFDA Orphan Drug Designation for Usnoflast in ALS treatment

Orphan drug designation offers development incentives and potential market exclusivity Zydus has announced that the USFDA has granted Orphan Drug

AstraZeneca receives positive recommendations for lung cancer treatments

NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care AstraZeneca has received two positive recommendations from the National Institute

Innovative Health Initiative launches a trial aimed at ending Crohn’s Disease

Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset In a landmark effort, the INTERCEPT project has launched Europe’s

EC approves lazertinib in combination with amivantamab for NSCLC patients

Combination therapy shows superior survival benefit over standard treatment The European Commission (EC) has approved the marketing authorisation for LAZCLUZE

AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025

Preclinical data highlights potential in treating Alzheimer’s disease AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been

Datapharm expands into US market through partnership with phactMI

Collaboration aims to enhance accessibility of medicines information Datapharm has announced its expansion into the United States through a new

UK sees 70% increase in phase I advanced therapy clinical trials in 2024

Cell and Gene Therapy Catapult reveals significant growth in UK trials The UK experienced a notable increase in advanced therapy

Gilead and LEO Pharma partner to develop oral STAT6 program

Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic partnership to

Actinogen boosts trial with Cambridge Cognition’s digital suite

Partnership aims to advance Alzheimer’s research with innovative tools Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

New partnership to advance precision medicine in lung cancer diagnosis Biofidelity and CellCarta have announced a strategic partnership to utilise

Oxford Drug Design achieves in vivo validation for novel cancer treatment

Promising results from mouse study lead to expanded trials Oxford Drug Design, the Oxford-based AI drug discovery company, has announced

Owlstone Medical announces $27 million USD first close in Series E financing round

Funds to accelerate commercialisation and clinical trials of diagnostic tests Owlstone Medical has announced a first close of $27 million

Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation

Pheno Therapeutics granted trial authorisation for MS candidate

First-in-human trial of PTD802 to commence following UK MHRA approval Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from

Gilead and LEO Pharma partner to develop oral STAT6 program

Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic partnership to

AI set to revolutionise pharmaceutical R&D says GlobalData

Survey finds AI to enhance productivity and cut costs in the next 12 months AI is poised to significantly lower

Patients pleased? – PharmaTimes

Debra is late getting up for work again. In her heart of hearts, she’s not really enjoying her job as

NICE recommends olaparib for BRCA-mutated breast cancer treatment

Groundbreaking approval provides new hope for patients in England and Wales The National Institute for Health and Care Excellence (NICE)

New therapy hope for prostate cancer patients

CR-discovered NXP800 shows promise in clinical trials Prostate cancer resistant to hormone therapy could soon have a new treatment option.

Angelini Ventures co-leads Series A financing in Neumirna Therapeutics

Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million Series A financing

Cambridge Cognition highlights positive Cantab results

New FDA-approved schizophrenia treatment shows promise in clinical trials Cambridge Cognition has praised Bristol Myers Squibb for the FDA approval

Merck unveils new cyber-physical trust platform at CES 2025

M-Trust set to improve product safety and counterfeiting solutions Merck has launched the beta version of M-Trust, a pioneering cyber-physical

Novartis gene therapy set to enhance SMA treatment

OAV101 IT expands potential for type II SMA patients Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec

Amgen’s lung cancer treatment gets conditional approval

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products Regulatory Agency

New prostate cancer test cuts biopsies by 50% in US

EpiSwitch PSE shows promise in reducing unnecessary procedures Kearney Urology Center has reported a 50% reduction in biopsies since adopting

FDA approves Sequana Medical’s Alfapump for ascites treatment

FDA gives green light to innovative device for liver conditions Sequana Medical NV has announced the US FDA approval of

NHS Confederation welcomes social care commission announcement

Government announces independent commission on social care The government has announced the creation of an independent commission on social care.

UK regulator warns against buying weight-loss medicines without prescription

MHRA urges caution over illegal medicines from beauty salons and social media The Medicines and Healthcare products Regulatory Agency (MHRA)

EC approves Rybrevant with Lazcluze for advanced lung cancer

New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European

Beckley Psytech announces positive results for ELE-101 in depression trial

Phase 2a study shows promising antidepressant effects Beckley Psytech has announced positive topline results from its phase 2a study of

German cancer centre treats first patient with Elekta Evo

New CT-guided radiotherapy system offers personalised cancer treatment Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world

MindMed begins phase 3 study of MM120 for anxiety disorder

First patient dosed in landmark trial for GAD treatment MindMed has announced the dosing of the first patient in its

CSL receives positive opinion for garadacimab in hereditary angioedema

New treatment could revolutionise care for HAE patients Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA)

Leriglitazone meets primary endpoint in pivotal cALD trial

Promising trial results support marketing authorisation application Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary

Bayer begins inhibitor study treating advanced KRAS-mutated tumours

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264,

Leriglitazone meets endpoint in trial for cerebral adrenoleukodystrophy

Promising results set stage for European marketing authorization Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary

iOnctura achieves new clinical milestones in uveal melanoma therapy

Successful phase 1 study highlights potential of roginolisib iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing

CatalYm shows potential of visugromab for treating cachexia

New findings presented at international SCWD conference CatalYm has announced promising new data on its lead drug candidate, visugromab, at

Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis

New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its T-regulatory

Poolbeg Pharma presents positive results for POLB 001

promising pre-clinical data on preventing cytokine release syndrome Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at

Imfinzi receives NICE recommendation for lung cancer treatment

Trial results lead to new treatment option for lung cancer AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended

NICE endorses Neuraxpharm’s ublituximab for treating MS

New antibody therapy shows promise in managing condition Neuraxpharm Group has announced that the National Institute for Health and Care

Teva’s Ajovy shows positive results in preventing pediatric migraines

Phase 3 trial indicates significant efficacy and safety for children and adolescents Teva Pharmaceutical Industries has presented positive data from

Everest therapy shows promise in nephropathy trial

Data highlights effectiveness of EVER001 in treating pMN Everest Medicines has announced promising results from the Phase 1b/2a clinical trial

Antag Therapeutics secures €80 million in weight loss therapy financing

Versant Ventures leads investment round to advance drug Antag Therapeutics has announced the closing of an €80 million Series A

Orbit Discovery and Evergreen Theragnostics expand research collaboration

Partnership aims to develop new radiopharmaceuticals for cancer treatment Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in

KIMMTRAK recommended for funding by NICE for uveal melanoma patients

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and

Pharma giants vie for oral GLP-1R approval

Race to create first oral drug for obesity intensifies The competition to gain approval for the first oral GLP-1R drug

OGT launches enhanced genetic profiling panel for CLL

New SureSeq CLL + CNV V3 panel improves understanding of CLL OGT has announced the launch of its enhanced SureSeq

UK grants promising innovative medicine status to CIDP drug

Therapy for autoimmune disorder shows potential Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status

New injection offers hope for asthma and COPD attacks

Injection significantly reduces need for further treatment A new treatment for asthma and COPD attacks could revolutionise patient care, scientists

Code makers – PharmaTimes

2024 ABPI Code update has launched – what’s next for pharma and QR codes? The long-anticipated update to the ABPI

Rab Prinjha – PharmaTimes

Curve Therapeutics has appointed Rab Prinjha as Chief R&D Officer Curve Therapeutics has appointed Rab Prinjha as Chief Research and Development (R&D) Officer. Rab is a

Mind the gap

How industry and the NHS can work together to bridge the diagnostic gap in COPD

To be precise – PharmaTimes

How oncology therapies can stand out in a diverse, uncertain landscape The oncology field is rapidly evolving, particularly with the

Mikkel Wandahl Pedersen – PharmaTimes

Commit Biologics has appointed Mikkel Wandahl Pedersen as CSO Commit Biologics has announced the appointment of Mikkel Wandahl Pedersen as

Dr Lara Boyd – PharmaTimes

Tessellate BIO has appointed Dr Lara Boyd as CBO Tessellate BIO has appointed Dr Lara Boyd as Chief Business Officer. Lara joins

Siva Anandaciva – PharmaTimes

The King’s Fund has appointed Siva Anandaciva as Director of Policy, Events and Partnerships The King’s Fund has appointed Siva

4 ways AI is shaping the future of Life Sciences

There’s no denying it; pharma is in its innovation era. The life sciences industry is already undergoing a massive revolution,

Dr Daniel Mahony – PharmaTimes

Mahony will continue as the UK government’s Life Sciences Investment Envoy The Department for Science, Innovation and Technology has announced

Cytomos raises $5m to scale up cell analysis technology production

The biotech will use the funding to drive sales of its first commercial product Cytomos has announced that it has

Anthony Harnden – PharmaTimes

The MHRA has appointed Anthony Harnden as Chair The Medicine and Healthcare products Regulatory Agency (MHRA) has appointed Anthony Harnden,

Ardena’s expanded nanomedicine facility granted full GMP approval

The Netherlands facility is designed to handle a wide range of nanomedicines, including lipid-based nanoparticles Ardena has announced the full

New PAGB research highlights importance of self-care for easy-to-treat conditions

The census found that 56% of people visit their GP for a UTI and 27% for thrush New research from

Dr Rima Makarem – PharmaTimes

Somerset NHS Foundation Trust has appointed Dr Rima Makarem as Chair Somerset NHS Foundation Trust has appointed Dr Rima Makarem,

Teva and Immunai partner to improve clinical decision making

The companies will focus on mechanisms of action, dose selection and biomarker analyses Teva Pharmaceuticals and artificial intelligence (AI)-driven Immunai

Vivolta and Neurochase to produce brain therapy catheters

New long-term partnership to address neurological disorder treatments Vivolta, a specialist in medical electrospinning solutions, has entered a long-term partnership

AC immune announces positive trial results for early Parkinson’s treatment

Therapy shows high efficacy in initial trial phase AC Immune SA has reported encouraging interim results from its phase 2

Osivax begins phase 2a booster trial for influenza vaccine

First participant vaccinated in study of ovx836 booster dose Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious

Microbiotica begins human trials for ulcerative colitis treatment

First patient dosed in phase 1b trial of MB310 therapy Microbiotica, a clinical-stage biopharma company, has announced the dosing of

Infinitopes to showcase cancer vaccine breakthroughs at SITC

Insight into double-blind, phase i/ii clinical trial for oesophageal cancer Infinitopes, an integrated cancer biotech firm, will present its pioneering

Lupin to develop near-zero global warming inhalers

Eco-friendly inhalers aim to reduce environmental impact Lupin Healthcare UK Ltd has announced plans to reformulate its pMDI inhalers with

Scottish medicines consortium approves CAR T-cell therapy for blood cancer

First car t-cell therapy accepted for second-line treatment in Scotland The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell

SMC recommends Yselty for treating uterine fibroids

New treatment option approved for women in Scotland The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for treating moderate

Trial transformers – PharmaTimes

Building strong partnerships with sites for more effective clinical trials When I first entered the clinical research industry more than

Elsevier backs Pistoia Alliance for AI in drug discovery

New initiatives to tackle AI-related challenges in life sciences Elsevier, a leader in information and analytics, has announced its support

New study to assess mpox vaccine in pregnant women and infants

Trial to evaluate safety and efficacy of MVA-BN vaccine A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant

MHRA grants approval for bladder cancer drug erdafitinib

New therapy targets specific genetic alterations, promises extended survival Johnson & Johnson has announced that the UK’s Medicines and Healthcare

Arcellx to present positive data on multiple myeloma treatments

Phase 1 and 2 studies show promising results for anito-cel therapy Arcellx Inc, a biotechnology firm focused on cell therapy

Dr Jane Rhodes – PharmaTimes

AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer (CEO) and member of the Board,

A rare opportunity – PharmaTimes

Importance of continuous collaboration with rare disease communities At Blueprint Medicines, we aim to make a significant difference in patients’

Anthony Hemmerdinger – PharmaTimes

Walgreens Boots Alliance appoints Anthony Hemmerdinger as MD, UK and Ireland Walgreens Boots Alliance has announced the appointment of Anthony Hemmerdinger as Managing Director of

UK dementia clinical trial participation set to boost by ‘tens of thousands’

The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the

NICE recommends remote monitoring technology for heart failure patients

Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020 The National Institute for Health and

WHO report highlights resurgence of tuberculosis

Approximately 8.2 million people were diagnosed with the infectious disease in 2023 The World Health Organization’s (WHO) newly published report

Ian Keith – PharmaTimes

Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith, who has

NICE recommendation for new Alexion PNH treatment

danicopan shown to improve haemoglobin levels and reduce anaemia Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health

Laura Vergani – PharmaTimes

Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined

Calluna Pharma completes successful phase 1 trial of new fibrotic disease drug

CAL101 shows promising results and is set to enter phase 2 development Calluna Pharma AS has announced the successful completion

Darzalex subcutaneous regimen approved by European Commission

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of

Valneva Scotland announces year-long support for local cancer charity Team Jak

The company’s workforce will volunteer and fundraise for Team Jak throughout the year Valneva Scotland has partnered with Team Jak,

Learna and University of Wolverhampton launch flexible healthcare courses

The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University of Wolverhampton

NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension

Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for

Transgene’s cancer vaccine trial shows mixed results

Phase 2 study of TG4001 shows promise in cervical cancer patients Transgene, a biotech company specializing in virus-based immunotherapies for

Vivan renews five-year lease at UK biotech hub White City Place

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a

New £4.5m initiative launched to address UK medicines manufacturing skills shortage

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address

Richard Hopkins – PharmaTimes

NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its

HBC Immunology shares promising results for prostate cancer co-therapy

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an

Alleo and Ubiquigent unite to accelerate drug discovery

Partnership to harness AI for DUB-focused preclinical programmes

Celltrion unveils promising dose escalation results for subcutaneous infliximab

Study reveals potential new strategy for managing inflammatory bowel disease

Lundbeck to acquire Longboard Pharmaceuticals in strategic deal

Acquisition to enhance Lundbeck’s neuroscience pipeline Lundbeck has announced a significant step forward in its Focused Innovator strategy with the

Sanofi launches high-dose flu vaccine in the UK

New vaccine aims to protect older adults from severe flu complications Sanofi has announced the launch of its high-dose egg-based

Johnson & Johnson myeloma drug recommended for NHS use

Teclistamab offers hope for patients exhausting treatment options Teclistamab (Tecvayli), a drug manufactured by Johnson & Johnson, has received a

Heart patient goes home hours after live-streamed valve replacement

Sheffield cardiologists demonstrate cutting-edge TAVI procedure Cardiologists at Sheffield Teaching Hospitals NHS Foundation Trust have performed a cutting-edge heart valve

Purespring Therapeutics secures £80 million in Series B funding

New investment to advance gene therapies for kidney diseases Purespring Therapeutics has raised £80m in an oversubscribed Series B financing

Astellas and AviadoBio announce exclusive gene therapy deal

AviadoBio to receive up to £1.8 billion in potential payments AviadoBio and Astellas Pharma have entered into an exclusive option

Kyowa Kirin announces positive interim data for lymphoma treatment

Real-world studies show effectiveness of mogamulizumab in routine practice Kyowa Kirin International (KKI) has announced positive interim findings from three

Scottish patients first in UK to access new lung cancer treatment

Scottish Medicines Consortium recommends pembrolizumab The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy for adults

FluoGuide submits clinical trial application for head and neck cancer treatment

Biotech company moves forward with phase 2 trial for precision cancer surgery Copenhagen-based biotech company FluoGuide A/S has announced the

ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study

Largest real-world study demonstrates significant survival advantage In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly

IRLAB’s new drug shows promise in treating apathy in Parkinson’s patients

Phase 1 trial of IRL757 demonstrates good absorption and safety profile IRLAB Therapeutics AB has announced the successful completion of

AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference

Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid AlzeCure Pharma AB, a company specializing in drugs

Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy

ISM001-055 shows promise in improving lung function among patients Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, has announced

European Commission approves Yuvanci for pulmonary arterial hypertension treatment

Janssen-Cilag therapy becomes the first single tablet combination therapy for PAH in europe The European Commission has approved Yuvanci (macitentan

Great company – PharmaTimes

ICON celebrates 2024 ‘company of the year’ win ICON continues to celebrate its achievement at the 2024 Clinical Researcher of

Lots in translation – PharmaTimes

Harnessing vital patient data for precision in clinical trials In clinical research, leveraging patient data has become a critical factor

Dr Alex Dickinson – PharmaTimes

Sphere Fluidics has appointed Dr Alex Dickinson to its Board of Directors Sphere Fluidics has announced the appointment of Dr Alex Dickinson to

Oxford drug design secures funding to combat cystic fibrosis lung infections

£3m programme to accelerate new antimicrobial treatment Oxford Drug Design has been awarded a share of a £3 million Collaborative

Sheffield A&E to implement life-saving HIV and hepatitis testing

New government scheme to offer routine opt-out blood tests Starting next week, Sheffield’s Northern General Hospital A&E Department will begin

Fabio Gratton – PharmaTimes

minds + assembly has appointed Fabio Gratton as an Advisor minds + assembly welcomes Fabio Gratton as an Advisor to

Dr Amy Walker – PharmaTimes

4basebio has announced Dr Amy Walker as Chief Operating Officer 4basebio has announced the appointment of Dr Amy Walker as

AlgoTx completes pivotal phase 2 trial for ground-breaking CIPN treatment

International trial marks leap forward in chemotherapy-induced neuropathy care In a landmark announcement from Paris, AlgoTherapeutix (AlgoTx) has heralded the

Cancer Grand Challenges launches global initiative to take on toughest problems

International think tanks to shape future of cancer research funding Cancer Grand Challenges, a pioneering initiative co-founded by Cancer Research

Russell Abberley – PharmaTimes

ABPI has appointed Russell Abberley as Acting President The Association of the British Pharmaceutical Industry (ABPI) has appointed Russell Abberley

Sundip Chahal – PharmaTimes

Milieu Insight has appointed Sundip Chahal as Chief Executive Officer Milieu Insight has appointed Sundip Chahal (pictured left), former YouGov

Oncologica to advance urine-based prostate cancer screening test

There is currently no national screening programme for the disease in the UK Oncologica has developed a urine-based screening test

FlyPharma Europe, Vienna – October 2024 conference

The conference will return to Vienna AirportCity on 23 to 24 October 2024 Samedan has announced that on 23 to

NHS Trust to evaluate AI software for prostate cancer diagnosis

It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time Leeds Teaching Hospitals NHS

Jane Osbourn – PharmaTimes

Alchemab has appointed Jane Osbourn as Chief Executive Officer Alchemab Therapeutics has appointed Jane Osbourn, the company’s Co-Founder and Chief

UKRI’s MRC awards £27.4m to University of Dundee research unit

The centre aims to discover new drug targets for diseases such as Parkinson’s and hypertension The UK Research and Innovation’s

WHO adds first mpox vaccine to prequalification list

The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex The World Health Organization (WHO) has announced that

Nxera and Cancer Research UK to present promising cancer drug trial at ESMO

Innovative immunotherapy drug HTL0039732 shows potential in trials Nxera Pharma and Cancer Research UK are set to present their ongoing

World Sepsis Day 2024 highlights need for better sepsis treatments

GlobalData emphasises importance of Improved clinical trials World Sepsis Day, observed annually on 13 September, aims to raise awareness about

Chemical reaction – PharmaTimes

Chemistry is the cornerstone of modern civilisation, playing a crucial role in virtually every aspect of our lives. From the

Centessa reports positive phase 1 clinical data for ORX750

Promising results for novel orexin agonist in sleep-deprived volunteers Nxera Pharma, formerly known as Sosei Group, has announced that its

HRT linked to reduced psychosis relapse risk in menopausal women

New study highlights potential benefits of menopausal hormone therapy A recent study published in the American Journal of Psychiatry suggests